A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients

An analytical assay has been developed and validated for ultrafast and high-throughput mass spectrometric determination of pemetrexed concentrations in plasma using matrix assisted laser desorption/ionization–triple quadrupole–tandem mass spectrometry. Patient plasma samples spiked with the internal...

Descripción completa

Detalles Bibliográficos
Autores principales: Meesters, Roland J. W., Cornelissen, Robin, van Klaveren, Rob J., de Jonge, Robert, den Boer, Ethan, Lindemans, Jan, Luider, Theo M.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Technical Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990004/
https://www.ncbi.nlm.nih.gov/pubmed/20865407
http://dx.doi.org/10.1007/s00216-010-4192-8
_version_ 1782192421934727168
author Meesters, Roland J. W.
Cornelissen, Robin
van Klaveren, Rob J.
de Jonge, Robert
den Boer, Ethan
Lindemans, Jan
Luider, Theo M.
author_facet Meesters, Roland J. W.
Cornelissen, Robin
van Klaveren, Rob J.
de Jonge, Robert
den Boer, Ethan
Lindemans, Jan
Luider, Theo M.
author_sort Meesters, Roland J. W.
collection PubMed
description An analytical assay has been developed and validated for ultrafast and high-throughput mass spectrometric determination of pemetrexed concentrations in plasma using matrix assisted laser desorption/ionization–triple quadrupole–tandem mass spectrometry. Patient plasma samples spiked with the internal standard methotrexate were measured by multiple reaction monitoring. The detection limit was 0.4 fmol/μL, lower limit of quantification was 0.9 fmol/μL, and upper limit of quantification was 60 fmol/μL, respectively. Overall observed pemetrexed concentrations in patient samples ranged between 8.7 (1.4) and 142.7 (20.3) pmol/μL (SD). The newly developed mass spectrometric assay is applicable for (routine) therapeutic drug monitoring of pemetrexed concentrations in plasma from non-small cell lung cancer patients.
format Text
id pubmed-2990004
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-29900042010-12-15 A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients Meesters, Roland J. W. Cornelissen, Robin van Klaveren, Rob J. de Jonge, Robert den Boer, Ethan Lindemans, Jan Luider, Theo M. Anal Bioanal Chem Technical Note An analytical assay has been developed and validated for ultrafast and high-throughput mass spectrometric determination of pemetrexed concentrations in plasma using matrix assisted laser desorption/ionization–triple quadrupole–tandem mass spectrometry. Patient plasma samples spiked with the internal standard methotrexate were measured by multiple reaction monitoring. The detection limit was 0.4 fmol/μL, lower limit of quantification was 0.9 fmol/μL, and upper limit of quantification was 60 fmol/μL, respectively. Overall observed pemetrexed concentrations in patient samples ranged between 8.7 (1.4) and 142.7 (20.3) pmol/μL (SD). The newly developed mass spectrometric assay is applicable for (routine) therapeutic drug monitoring of pemetrexed concentrations in plasma from non-small cell lung cancer patients. Springer-Verlag 2010-09-25 2010 /pmc/articles/PMC2990004/ /pubmed/20865407 http://dx.doi.org/10.1007/s00216-010-4192-8 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Technical Note
Meesters, Roland J. W.
Cornelissen, Robin
van Klaveren, Rob J.
de Jonge, Robert
den Boer, Ethan
Lindemans, Jan
Luider, Theo M.
A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
title A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
title_full A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
title_fullStr A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
title_full_unstemmed A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
title_short A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
title_sort new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
topic Technical Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990004/
https://www.ncbi.nlm.nih.gov/pubmed/20865407
http://dx.doi.org/10.1007/s00216-010-4192-8
work_keys_str_mv AT meestersrolandjw anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT cornelissenrobin anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT vanklaverenrobj anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT dejongerobert anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT denboerethan anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT lindemansjan anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT luidertheom anewultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT meestersrolandjw newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT cornelissenrobin newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT vanklaverenrobj newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT dejongerobert newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT denboerethan newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT lindemansjan newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients
AT luidertheom newultrafastandhighthroughputmassspectrometricapproachforthetherapeuticdrugmonitoringofthemultitargetedantifolatepemetrexedinplasmafromlungcancerpatients

Ejemplares similares